A detailed history of State Street Corp transactions in Arcellx, Inc. stock. As of the latest transaction made, State Street Corp holds 1,544,939 shares of ACLX stock, worth $127 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,544,939
Previous 1,755,664 12.0%
Holding current value
$127 Million
Previous $96.9 Million 33.15%
% of portfolio
0.01%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$50.91 - $86.61 $10.7 Million - $18.3 Million
-210,725 Reduced 12.0%
1,544,939 $129 Million
Q2 2024

Aug 14, 2024

SELL
$49.74 - $66.98 $6.44 Million - $8.67 Million
-129,454 Reduced 6.87%
1,755,664 $96.9 Million
Q1 2024

May 15, 2024

BUY
$51.85 - $73.49 $5.77 Million - $8.18 Million
111,279 Added 6.27%
1,885,118 $131 Million
Q4 2023

Feb 14, 2024

SELL
$31.75 - $57.99 $7.63 Million - $13.9 Million
-240,406 Reduced 11.94%
1,773,839 $98.4 Million
Q3 2023

Nov 14, 2023

BUY
$31.51 - $37.4 $2.6 Million - $3.08 Million
82,480 Added 4.27%
2,014,245 $72.3 Million
Q2 2023

Aug 14, 2023

BUY
$27.49 - $46.9 $1.58 Million - $2.69 Million
57,309 Added 3.06%
1,931,765 $61.1 Million
Q1 2023

May 15, 2023

BUY
$26.92 - $33.94 $6.96 Million - $8.77 Million
258,365 Added 15.99%
1,874,456 $57.8 Million
Q4 2022

Feb 14, 2023

BUY
$17.18 - $33.0 $1.75 Million - $3.37 Million
102,066 Added 6.74%
1,616,091 $50.1 Million
Q3 2022

Nov 15, 2022

BUY
$16.67 - $22.04 $22.3 Million - $29.5 Million
1,338,208 Added 761.14%
1,514,025 $28.4 Million
Q2 2022

Aug 15, 2022

BUY
$7.21 - $24.43 $755,694 - $2.56 Million
104,812 Added 147.61%
175,817 $3.18 Million
Q1 2022

May 16, 2022

BUY
$12.97 - $19.14 $920,934 - $1.36 Million
71,005 New
71,005 $995,000

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $3.6B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.